MP-424

Tanabe Pharma Corporation · Phase 3 active Small molecule

MP-424 is a HCV NS3/4A protease inhibitor Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Chronic hepatitis C virus infection. Also known as: Telaprevir.

MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.

MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins. Used for Chronic hepatitis C virus infection.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

• Baseline phase 3 → approval rate +58.3pp
  Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MP-424
Also known as	Telaprevir
Sponsor	Tanabe Pharma Corporation
Drug class	HCV NS3/4A protease inhibitor
Target	HCV NS3/4A protease
Modality	Small molecule
Therapeutic area	Virology/Hepatology
Phase	Phase 3

Mechanism of action

MP-424 binds to and inhibits the HCV NS3/4A serine protease, an enzyme essential for processing the HCV polyprotein into functional viral proteins. By blocking this protease activity, the drug prevents viral replication and reduces HCV viral load in infected patients. This mechanism is part of direct-acting antiviral (DAA) therapy for chronic hepatitis C.

Approved indications

• Chronic hepatitis C virus infection

Common side effects

• Nausea
• Headache
• Fatigue
• Diarrhea

Key clinical trials

• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
• Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
• A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
• Safety and PK Study of MP-424 to Treat Chronic Hepatitis C (PHASE1)
• Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
• Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (PHASE3)
• Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MP-424 CI brief — competitive landscape report
• MP-424 updates RSS · CI watch RSS
• Tanabe Pharma Corporation portfolio CI

Frequently asked questions about MP-424

What is MP-424?

MP-424 is a HCV NS3/4A protease inhibitor drug developed by Tanabe Pharma Corporation, indicated for Chronic hepatitis C virus infection.

How does MP-424 work?

MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.

What is MP-424 used for?

MP-424 is indicated for Chronic hepatitis C virus infection.

Who makes MP-424?

MP-424 is developed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).

Is MP-424 also known as anything else?

MP-424 is also known as Telaprevir.

What drug class is MP-424 in?

MP-424 belongs to the HCV NS3/4A protease inhibitor class. See all HCV NS3/4A protease inhibitor drugs at /class/hcv-ns3-4a-protease-inhibitor.

What development phase is MP-424 in?

MP-424 is in Phase 3.

What are the side effects of MP-424?

Common side effects of MP-424 include Nausea, Headache, Fatigue, Diarrhea.

What does MP-424 target?

MP-424 targets HCV NS3/4A protease and is a HCV NS3/4A protease inhibitor.

Related

• Drug class: All HCV NS3/4A protease inhibitor drugs
• Target: All drugs targeting HCV NS3/4A protease
• Manufacturer: Tanabe Pharma Corporation — full pipeline
• Therapeutic area: All drugs in Virology/Hepatology
• Indication: Drugs for Chronic hepatitis C virus infection
• Also known as: Telaprevir